Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9550 monotherapy and AZD6234 + AZD9550 in overweight/obese Chinese adults (Substudy 2)
CTR20254912Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of AZD9550, lenbelintide in obesity, Overweight, sponsored by AstraZeneca. Started Dec 2025; status: active.
02
Drugs
AZD9550lenbelintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20254912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254912.